Abstract
There is a wealth of epidemiological and clinical data linking low-density lipoprotein cholesterol (LDLc) with atherosclerotic cardiovascular disease. Numerous primary and secondary prevention trials have demonstrated that reduction in LDLc leads to significant decrease in cardiovascular event rates. However, patients continue to be at significant risk for recurrent events despite aggressive LDLc lowering, reflecting a substantial residual risk. Numerous parameters like apolipoprotein B, LDL particle size, number and non-high density lipoprotein cholesterol (non-HDLc) measurement have been used to assess and address this high residual risk. Herein, we discuss the rationale and the evidence supporting the use of non-HDLc. We also discuss therapeutic options and provide a practical approach to residual risk reduction from a primary care perspective.
| Original language | English |
|---|---|
| Pages (from-to) | 434-437 |
| Number of pages | 4 |
| Journal | Southern Medical Journal |
| Volume | 103 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2010 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Targeting residual risk : The rationale for the use of non-HDL cholesterol. / Alla, Venkata (Mahesh); Kaushik, Manu; Mooss, Aryan N.
In: Southern Medical Journal, Vol. 103, No. 5, 05.2010, p. 434-437.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Targeting residual risk
T2 - The rationale for the use of non-HDL cholesterol
AU - Alla, Venkata (Mahesh)
AU - Kaushik, Manu
AU - Mooss, Aryan N.
PY - 2010/5
Y1 - 2010/5
N2 - There is a wealth of epidemiological and clinical data linking low-density lipoprotein cholesterol (LDLc) with atherosclerotic cardiovascular disease. Numerous primary and secondary prevention trials have demonstrated that reduction in LDLc leads to significant decrease in cardiovascular event rates. However, patients continue to be at significant risk for recurrent events despite aggressive LDLc lowering, reflecting a substantial residual risk. Numerous parameters like apolipoprotein B, LDL particle size, number and non-high density lipoprotein cholesterol (non-HDLc) measurement have been used to assess and address this high residual risk. Herein, we discuss the rationale and the evidence supporting the use of non-HDLc. We also discuss therapeutic options and provide a practical approach to residual risk reduction from a primary care perspective.
AB - There is a wealth of epidemiological and clinical data linking low-density lipoprotein cholesterol (LDLc) with atherosclerotic cardiovascular disease. Numerous primary and secondary prevention trials have demonstrated that reduction in LDLc leads to significant decrease in cardiovascular event rates. However, patients continue to be at significant risk for recurrent events despite aggressive LDLc lowering, reflecting a substantial residual risk. Numerous parameters like apolipoprotein B, LDL particle size, number and non-high density lipoprotein cholesterol (non-HDLc) measurement have been used to assess and address this high residual risk. Herein, we discuss the rationale and the evidence supporting the use of non-HDLc. We also discuss therapeutic options and provide a practical approach to residual risk reduction from a primary care perspective.
UR - http://www.scopus.com/inward/record.url?scp=77951795467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951795467&partnerID=8YFLogxK
U2 - 10.1097/SMJ.0b013e3181d7e3a8
DO - 10.1097/SMJ.0b013e3181d7e3a8
M3 - Review article
VL - 103
SP - 434
EP - 437
JO - Southern Medical Journal
JF - Southern Medical Journal
SN - 0038-4348
IS - 5
ER -